Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Swiss - Delayed Quote CHF

Cosmo Pharmaceuticals N.V. (COPN.SW)

47.55
+0.25
+(0.53%)
As of 10:33:51 AM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
266,788
266,788
92,780
102,089
65,074
Cost of Revenue
19,865
19,865
19,089
18,762
15,140
Gross Profit
246,923
246,923
73,691
83,327
49,934
Operating Expense
92,014
92,014
67,536
55,270
38,833
Operating Income
154,909
154,909
6,155
28,057
11,101
Net Non Operating Interest Income Expense
1,549
1,549
-4,576
-6,331
-6,409
Pretax Income
153,367
153,367
-6,489
24,473
24,003
Tax Provision
20,176
20,176
4,214
6,968
2,330
Net Income Common Stockholders
133,236
133,236
-10,783
17,225
21,672
Diluted NI Available to Com Stockholders
133,236
133,236
-10,783
17,225
21,672
Basic EPS
8.14
8.14
-0.67
1.05
1.29
Diluted EPS
8.12
8.12
-0.67
1.05
1.28
Basic Average Shares
16,358.81
16,358.81
16,105.13
16,425.40
16,842.05
Diluted Average Shares
16,417.79
16,417.79
16,105.13
16,425.40
16,904.06
Total Operating Income as Reported
148,882
148,882
-1,875
28,057
11,101
Rent Expense Supplemental
--
--
144
120
117
Total Expenses
111,879
111,879
86,625
74,032
53,973
Net Income from Continuing & Discontinued Operation
133,236
133,236
-10,783
17,225
21,672
Normalized Income
136,806.18
136,806.18
-595.39
17,236.44
21,781.25
Interest Income
1,669
1,669
4,068
2,941
3,062
Interest Expense
53
53
8,526
9,159
8,990
Net Interest Income
1,549
1,549
-4,576
-6,331
-6,409
EBIT
153,420
153,420
2,037
33,632
32,993
EBITDA
165,705
165,705
13,886
47,488
40,362
Reconciled Cost of Revenue
19,865
19,865
19,089
18,762
15,140
Reconciled Depreciation
12,285
12,285
11,849
13,856
7,369
Net Income from Continuing Operation Net Minority Interest
133,236
133,236
-10,783
17,225
21,672
Total Unusual Items Excluding Goodwill
-4,111
-4,111
-11,134
-16
-121
Total Unusual Items
-4,111
-4,111
-11,134
-16
-121
Normalized EBITDA
169,816
169,816
25,020
47,504
40,483
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-540.82
-540.82
-946.39
-4.56
-11.75
12/31/2021 - 3/12/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NVSEF Novartis AG
111.41
0.00%
 
NOV.DE Novo Nordisk A/S
53.57
-2.53%
 
AMRN Amarin Corporation plc
11.18
+7.92%
 
ROG.SW Roche Holding AG
261.60
-0.27%
 
AMGN Amgen Inc.
279.84
+0.70%
 
BMY Bristol-Myers Squibb Company
48.69
+0.33%
 
JNJ Johnson & Johnson
154.93
-0.29%
 
MRK Merck & Co., Inc.
79.84
+1.40%
 
ABBV AbbVie Inc.
180.37
+1.88%
 
LLY Eli Lilly and Company
859.73
+3.65%